Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 12 Month, Multicenter, Randomized, Parallel, Open-Label Study, to Evaluate Renal Function and Efficacy of Everolimus With Basiliximab and Cyclosporine Microemulsion Discontinuation at 3 Month Post-Transplant Versus Minimization, in de Novo Kidney Transplant Recipients.

Next Previous
X
Search
Trial Profile

A 12 Month, Multicenter, Randomized, Parallel, Open-Label Study, to Evaluate Renal Function and Efficacy of Everolimus With Basiliximab and Cyclosporine Microemulsion Discontinuation at 3 Month Post-Transplant Versus Minimization, in de Novo Kidney Transplant Recipients.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 11 Aug 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ciclosporin (Primary) ; Basiliximab; Corticosteroids; Everolimus
  • Indications Renal transplant rejection
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CERTES02

    • Most Recent Events

    • 01 Nov 2011 Results published in Transplantation Proceedings.
    • 09 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 19 Aug 2010 Results from a pooled analysis (A2419 and A2423) were reported at the 23rd International Congress of the Transplantation Society.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top